Sign in
Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration
Sabin Dang, MD
Annual Meeting Talks
2023
Quality Assessment of a New Silicone-Free Syringe Developed for Intravitreal Injections
Gustavo Barreto de Melo, MD, PhD, FASRS
On Demand Cases, Courses, and Papers
2021
Impact of Intravitreal Anti-VEGF Therapy for Severe Non-Proliferative Diabetic Retinopathy (NPDR): Analyses Through a Monte-Carlo Simulation Model
Andrew A. Moshfeghi, MD, MBA, FASRS
Category: Pharmacology